Abstracts tagged "interleukins (IL)"

Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 410 • 2013 ACR/ARHP Annual Meeting
Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis
Lourdes Nuñez Atahualpa¹, Mauricio Figuroa Sanchez¹, Daniel Alberto Rocha Muñoz², Raul Vargas Ramirez³, Beatriz Teresita Martin Marquez⁴, Jorge Ivan Gamez Nava⁵, Laura González López⁶, Erika Martínez García³, Esther Sanchez Corona³, Marcelo Petri⁴, Rosa Navarro Hernandez³, Veronica Gonzalez Diaz⁷, Jorge Aguilar Arreola⁸, Ana Guisllaine Bernard Medina⁹, Alejandra Nuñez Atahualpa¹⁰, Javier Andrade Garduño¹⁰, Eduardo Gomez Bañuelos³ and Monica Vazquez Del Mercado^4,8, ¹Radiology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ²Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ³CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, ⁶Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, ⁷Reumatologia, Antiguo Hospital Civil de Guadalajara - Fray Antonio Alcalde, Guadalajara, Mexico, ⁸Rheumatology, Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, ⁹Rheumatology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ¹⁰Universidad Autónoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The main cause of death in rheumatoid arthritis patients are cardiovascular events which cannot be entirely explained by traditional risk factors, suggesting, that systemic…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 600 • 2012 ACR/ARHP Annual Meeting
Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS)
Luiza Krause¹, Ingrid Fert¹, Karine Labroquère², Muriel Andrieu², Gilles Chiocchia³ and Maxime A. Breban⁴, ¹Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104)-Université Paris Descartes (UMR-S 1016), Paris, France, ²Cochin Immunobiology Facility, Paris, France, ³Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France, ⁴Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France
Background/Purpose: HLA-B27/human β2m transgenic rats (B27-rats), a model of SpA develop spontaneous colitis and arthritis. It was recently shown in this model that IL-17 producing…
Abstract Number: 1492 • 2012 ACR/ARHP Annual Meeting
IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis
Yuko Ota¹, Yasushi Kawaguchi¹, Atsushi Kitani², Kae Takagi¹, Hisae Ichida¹, Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Mucosal Immunity Section, NIAID/NIH, Bethesda, MD
Background/Purpose: Interleukin (IL)-13 is a pleiotropic cytokine involved in T helper type 2 cell immune response and in the development of fibrotic conditions such as…
Abstract Number: 434 • 2012 ACR/ARHP Annual Meeting
IL-22 Mediated Pannus Formation in Autoimmune Arthritis Is PI3K/Akt/mTOR Dependent
Siba P. Raychaudhuri¹, Anupam Mitra¹, Ananya Datta Mitra², Christine Abria² and Smriti K. Raychaudhuri², ¹Rheumatology, VA Sacramento Medical CenterUC Davis School of Medicine, Mather, CA, ²Rheumatology, VA Sacramento Medical Center, Mather, CA
Background/Purpose: IL-22, a Th17 cytokine plays a key role in the formation of “pannus” in autoimmune arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis…
Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Pavel Belomestnov¹, Jennifer Hamilton², A. Thomas DiCioccio¹, Martine Jasson³ and Allen R. Radin⁴, ¹Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY
Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…
Abstract Number: 429 • 2012 ACR/ARHP Annual Meeting
The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4⁺t�ACD4⁺Foxp3⁺t Cell in Patients with Rheumatoid Arthritis
Ning Li¹, Tianrui Ma², Jie Han¹, Jieru Zhou¹ and Songguo Zheng³, ¹Rheumatology, Shanghai East Hospital, Shanghai, China, ²Rheumatology, Ningbo Pediatric Hospital, Ningbo, China, ³Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA
Background/Purpose: To investigate the apoptosis of CD4+T cell and Tregs in the pathogenesis and disease activity of rheumatoid arthritis patients. Methods: Isolated lymphocytes from human…
Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Roy Fleischmann², Martine Jasson³, Allen R. Radin⁴, Jennifer Hamilton⁵ and Tom W.J. Huizinga⁶, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting
Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Shouzou Ichinose², Mitsuaki Yanagida², Kazuhisa Iwabuchi², Keigo Ikeda³, Shinji Morimoto⁴, Megumi Morioka⁵, Yoshinari Takasaki⁶ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, ⁶Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…
Abstract Number: 2502 • 2012 ACR/ARHP Annual Meeting
Neutrophil Extracellular Trap-Associated Protein Activation of the Inflammasome Is Enhanced in Lupus M1 Macrophages
J. Michelle Kahlenberg¹, Carolyne K. Smith², Carmelo Carmona-Rivera¹ and Mariana J. Kaplan³, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Neutrophil extracellular traps (NETs) contain numerous bactericidal proteins and are an important defense mechanism against microorganisms. Clearance of NETs is impaired in a subset…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting
Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Maki Takayama², Yoshitaka Kimura², Kurumi Asako², Hajime Kono², Yasuo Ono¹ and Shunsei Hirohata³, ¹Department of Microbiology and Immunology, Teikyo University Shool of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].